Jazz Pharmaceuticals vs Sarepta Therapeutics
JAZZ and SRPT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and SRPT compare
Jazz Pharmaceuticals is the larger company, worth 9.2 times as much as Sarepta Therapeutics ($15.7B against $1.7B).
Jazz Pharmaceuticals grew revenue faster over the last twelve months (13.5% versus −18.9% for Sarepta Therapeutics).
Jazz Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 4.4% compared with −5.9% at Sarepta Therapeutics.
Sarepta Therapeutics scores higher on the StockData Score (11 against 7 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | SRPT |
|---|---|---|
| Size and price | ||
| Market cap | $15.7B | $1.7B |
| Share price | $241.55 | $16.07 |
| Change, 1 year | 76.7% | −10.7% |
| Change, 5 years | 88.2% | −79.9% |
| Beta (5Y) | 0.53 | 0.99 |
| Employees | 2,890 | 835 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 3 | 3 |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 78.7× | – |
| P/S | 3.3× | 0.9× (better) |
| P/B | 3.7× | 1.1× (better) |
| EV/EBITDA | 43.2× | – |
| P/FCF | 9.7× | 9.6× (better) |
| FCF yield | 10.3% | 10.4% (better) |
| Fair value | $110.08 | $104.78 |
| Margin of safety | −119% | 84.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.5% (better) | −18.9% |
| Revenue growth, 5Y average | 12.5% | 32.4% (better) |
| Profitability | ||
| Operating margin | 9.0% (better) | −2.5% |
| Net margin | 4.4% (better) | −5.9% |
| FCF margin | 34.4% (better) | 9.0% |
| Return on equity | 5.1% (better) | −7.6% |
| Return on invested capital | 4.5% (better) | −5.3% |
| Financial health | ||
| Debt / equity | 1.33 | 0.10 (better) |
| Net debt / EBITDA | 6.37 | – |
| Current ratio | 1.82 | 3.46 (better) |
| Altman Z-score | 1.97 (better) | −0.22 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.2% | 102% |
| Held by insiders | 3.4% | 5.9% |
| Insider net buying, 12 months | −$67.1M | −$417K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 9.3% | 19.4% |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- SRPT stock overview
- SRPT income statement
- SRPT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.